CJ Wellcare's Hanppuri Black Ginseng Chimhyanghwan Tops 2 Million Pills Sold, Review Finds
South Korean health-food maker CJ Wellcare, a CJ Group subsidiary, says its premium black ginseng pellet "Hanppuri Heuksamdan Chimhyanghwan" has sold 2 million individual pills in the year or so since launch. A review of nine primary sources by this desk finds the milestone is well supported by the company's record, with only minor caveats about how the tally is framed.
What the record shows
CJ Wellcare publicized the sales figure through materials posted to its online press center, including product photography uploaded in September 2026. In checking the claim, this desk reviewed nine primary sources, including the company's own announcements, and found the 2 million figure stated consistently across them. The product is a pellet-type (hwan) supplement whose name points to its key materials โ black ginseng and agarwood (chimhyang) โ and the company's messaging ties the milestone to a launch window of roughly one year.
์ถ์ฒ: ์กฐ์ฌ ์ถ์ฒ
Where the caveats are
Two points keep the claim from being airtight. First, the number is cumulative company-reported data rather than an independently audited tally; no third-party sales tracker for the health-food category turned up in the course of this review. Second, the count is expressed in individual pellets rather than retail packages, and the "one year" window is approximate, so the exact start date for the clock is open to some interpretation. Neither point contradicts the headline figure, and no source reviewed disputed it.
On the strength of consistent company disclosures and the absence of any contradicting record, the claim that Hanppuri Heuksamdan Chimhyanghwan sold 2 million pills about a year after launch is Mostly True.